首页> 美国卫生研究院文献>Frontiers in Oncology >Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome

【2h】

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome

机译：可测量的残余疾病引导治疗以防止急性骨髓白血病和髓细胞增强综合征复发

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Frontiers in Oncology
作者
Jonathan Pan; Daniel Altman; Lindsay Wilde;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 4
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：急性髓性白血病;骨髓细胞增生;可测量的残余疾病;低甲基化试剂;氮杂氨酸;干细胞移植;

相似文献

外文文献
中文文献
专利

1. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial [J] . Platzbecker Uwe, Middeke Jan Moritz, Sockel Katja, The lancet oncology . 2018,第12期

机译：可测量的残余疾病导向治疗含氮己酸酯，以防止骨髓增生综合征和急性髓性白血病患者的血液神学复发（Relaza2）：开放标签，多期，第2期试验
2. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia [J] . Vey Norbert, Prebet Thomas, Thalamas Claire, Leukemia and lymphoma . 2017,第7a8期

机译：阶段1剂量升级对口服eBEXINOSTAT用于治疗复发/难治性更高风险的髓细胞增强综合征，急性髓性白血病或急性淋巴细胞白血病患者
3. Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia [J] . Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Haematologica . 2021,第1期

机译：可测量的残留疾病监测提供了不充分的递送时间，以防止大多数核心结合因子急性髓性白血病患者的形态复发
4. Ras gene mutation in acute myeloid leukemia and Myelodysplastic syndromes: a meta-analysis of its occurrence and prognostic relevance [C] . Cheng Jingru, Wang Peng, Zhang Tai, International Conference on Advanced Materials and Computer Science . 2016

机译：RAS基因突变在急性髓性白血病和髓细胞增强综合征中：荟萃分析其发生和预后相关性
5. Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level [D] . Chen, Jiahao. 2018

机译：在干细胞水平上骨髓增生异常综合征进展为急性髓细胞性白血病
6. Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia [O] . Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, 2021

机译：可测量的残余疾病监测提供不充分的递送时间以防止大多数核心结合因子急性髓性白血病患者的形态复发
7. Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome [O] . Jonathan Pan, Daniel Altman, Lindsay Wilde 2020

机译：可测量的残余疾病引导治疗，以防止急性骨髓白血病和髓细胞增强综合征复发

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome

著录项

引文网络

相似文献

相关主题

期刊订阅